Abstract
Cyclin-dependent kinase 4/6 (CDK4/6) acts as a crucial point of regulation in the G1-to-S transition in the cell division cycle, its aberrant activation was found in various human cancers, leading to abnormal cell proliferation. Recent clinical trials have reported that combined with other small-molecule targeted therapies, CDK4/6 inhibitors increase overall survival and objective response rates in breast cancer (BC), non-small cell lung cancer (NSCLC), and head and neck squamous cell carcinoma (HNSCC). Notably, targeting CDK4/6 triggers an antitumor immune response, providing a potential combined application method for immunotherapy. In this review, we summarize underlying mechanism of targeting CDK4/6 in regulating antigen presentation, immune cell activation, and tumor immune microenvironment (TIME) remodeling and in producing synergistic effects with immune checkpoint blockade (ICB) in cancer clinical treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
